Skip to main content

Court Orders Valsartan Defendants To Submit Primary Findings

Court Orders Valsartan Defendants To Submit Primary Findings

Court Orders Valsartan Defendants To Submit Primary Findings

Introduction

According to a court order dated April 29, valsartan recall defendants should submit their findings outlined in the order by June 17, 2019. The core discovery will be limited only to valsartan medications and not losartan or irbesartan products. Any recall defendants failing to submit the findings should inform the court about their intention by May 27. A telephonic conference will be held on May 8, at 3:00 p.m., to finalize the terms of a Discovery Confidentiality Order, followed by an in-person conference on May 29 to finalize the parties’ Profile Forms and Short Form Complaints, as well as an Order regarding the parties’ group organization and leadership.

The recall began last year after carcinogenic nitrosamines were discovered in active pharmaceuticals ingredients manufactured by Zhejiang Huahai Pharmaceutical Co. which was due to some alteration in its production methods. Research shows nitrosamines are linked to gastrointestinal tract cancers, including colon cancer, stomach cancer, and esophageal cancer. Also, nitrosamines may cause liver cancer, kidney cancer, and pancreatic cancer. There are 50 valsartan lawsuits pending in the federal litigation underway in New Jersey. The proceeding involves over 40 valsartan recall defendants, including Zhejiang Huahai, Teva Pharmaceutical Industries Ltd., Mylan NV, and CVS Health Co.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

Oregon to Get $66M in Sackler Opioid Settlement

Categories: Opioids

Oregon will gain $66 million as part of a nationwide settlement with the Sackler family and Purdue Pharma, the makers of OxyContin. The funds will be used to expand and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!